Robert Negrin

Clinical Focus

• Cancer > Bone Marrow Transplant
• Cancer > Hematology
• Blood and Marrow Transplantation
• Hematology

Administrative Appointments

• Medical Director, Clinical Bone Marrow Transplantation Laboratory (1990 - present)
• Division Chief, Blood and Marrow Transplant Program, Stanford University (2000 - present)

Honors and Awards

• Fellowship, Damon Runyon-Walter Winchell Cancer Fund (1988-1991)
• Fellow, Jose Carreras International Leukemia Foundation (1993-1996)
• President, International Society of Cellular Therapy (2000-2002)
• Distinguished Clinical Scientist Award, Doris Duke Foundation (2004)
• President, American Society of Blood and Marrow Transplantation (2006-2007)

Professional Education

Postdoctoral Advisees

George Chen , Mareike Florek , Saar Gill , Dennis Leveson-Gower , Aaron Logan , Emanuela Sega

Graduate & Fellowship Program Affiliations

• Cancer Biology
• Immunology
• Medicine

Community & International Work

• Volunteer 

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Research projects in our laboratory are aimed at studying the biology of cell populations capable of inducing or suppressing graft vs host disease as well as cells capable of promoting a graft vs tumor effect. In particular we are studying:

1) The clinical utility of expanded cytotoxic cells for immunotherapy. We have developed animal models utilizing mice with severe combined immunodeficiency (SCID) which will accept human tumor cells or murine model systems of syngeneic and allogeneic transplantation. In some instances the tumor cells are transfected with the bioluminescent marker luciferase so that the tumor cell growth can be quantitatively tracked in living animals. Using these model system we are studying the clinical efficacy of the expanded cytotoxic cells.

2) The interaction between the cytotoxic effector cells and a variety of tumor cell targets is under study. The role of granzyme/perforin and fas mediated pathways as well as the cell surface molecule NKG2D in cytotoxicity is under study.

3) We are exploring the biological impact of phenotypically defined populations of regulatory T cells on graft vs host disease and graft vs tumor reactions.

4) We are utilizing bioluminescent techniques to study these complex biological processes by either labelling the tumor or effector cell populations with the light emitting luciferase gene such that small numbers of cells can be tracked non-invasively, sensively and quantitatively.

Clinical Trials

• Bone Marrow Grafting for Leukemia and Lymphoma Recruiting
• Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation Recruiting
• Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Recruiting
• A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft versus Host Disease Recruiting
• Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting

Publications

• Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation. Olson JA, Zeiser R, Beilhack A, Goldman JJ, Negrin RS. J Immunol. 2009; 183 (5): 3219-28
• Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowksy R, Laport GG. Bone Marrow Transplant. 2009
• Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R. Int J Cancer. 2009; 124 (1): 239-44
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Gill S, Olson JA, Negrin RS. Biol Blood Marrow Transplant. 2009; 15 (7): 765-76